The agreement grants Lupin the right to introduce Vonoprazan, an innovative treatment for Acid Peptic Disorders (APD), which include Gastroesophageal Reflux Disease (GERD) and Peptic Ulcer Disease (PUD)
Read MoreSubscribe to our newsletter to get updates on our latest news